EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 557 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR New insights on self-sampling for cervical cancer screening April 27, 2022 The Cancer Moonshot: Moving from Planning to Research November 19, 2018 BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... April 4, 2022 ¿El azúcar provoca cáncer? September 20, 2022 Load more HOT NEWS Evaluation of Primary and Secondary Prevention of Oral Cancer FDA Approves Lenvatinib Plus Pembrolizumab for Advanced Renal Cell Carcinoma EMA Recommends Granting a Marketing Authorisation for Lisocabtagene Maraleucel Studying Genes and Proteins Together Sheds New Light on Colon Cancer
